FDA — authorised 1 September 2022
- Application: BLA761173
- Marketing authorisation holder: FRESENIUS KABI USA
- Local brand name: STIMUFEND
- Indication: SOLUTION — INJECTION
- Status: approved
🇺🇸 STIMUFEND in United States
FDA authorised STIMUFEND on 1 September 2022
Marketing authorisations
FDA
- Status: approved
STIMUFEND in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Other approved in United States
Frequently asked questions
Is STIMUFEND approved in United States?
Yes. FDA authorised it on 1 September 2022; FDA has authorised it.
Who is the marketing authorisation holder for STIMUFEND in United States?
FRESENIUS KABI USA holds the US marketing authorisation.